Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
2004-5-11
pubmed:abstractText
Lipoprotein lipase (LPL) is one of the enzymes regulated by insulin and its plasma activity reflects insulin sensitivity. Although intravenous heparin injection is required to measure LPL activity, we can detect LPL mass in preheparin serum (Pr-LPL mass) by immunoassay. In this study, we examined whether Pr-LPL mass reflects insulin sensitivity. We measured Pr-LPL mass, insulin sensitivity (Si), and acute insulin release in response to a glucose bolus (AIRg) in subjects with normal glucose tolerance (NGT; n = 23), impaired glucose tolerance (IGT; n = 10), and Type II diabetes mellitus (DM; n = 48). Si and AIRg were determined by minimal model analysis. We also compared Pr-LPL mass with the homeostasis model assessment of insulin resistance (HOMA-R) and the urinary excretion of C-peptide (urine CPR). We found that Pr-LPL mass correlated significantly with Si ( r = 0.354, P < 0.01) in all the subjects. This correlation was still significant in the NGT group (P < 0.472, P < 0.05), DM group (r = 0.311, P < 0.01), and DM group with a fasting plasma glucose >150 mg/dl ( n = 20, r = 0.459. P < 0.05). Moreover, Pr-LPL mass correlated negatively with HOMA-R (r = -0.272. P < 0.05) and fasting IRI (r = -0.256, P < 0.05). By contrast, Pr-LPL mass was not correlated with either urine CPR or logAIRg that reflect the ability to secrete insulin. In conclusion, Pr-LPL mass reflects insulin sensitivity. We speculate that Pr-LPL mass might be used to assess insulin sensitivity not only in the general population but also in advanced diabetic patients.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jun
pubmed:issn
0021-9150
pubmed:author
pubmed:issnType
Print
pubmed:volume
174
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
385-90
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed-meshheading:15136071-Adult, pubmed-meshheading:15136071-Biological Markers, pubmed-meshheading:15136071-Cohort Studies, pubmed-meshheading:15136071-Diabetes Mellitus, Type 2, pubmed-meshheading:15136071-Female, pubmed-meshheading:15136071-Glucose Tolerance Test, pubmed-meshheading:15136071-Heparin, pubmed-meshheading:15136071-Humans, pubmed-meshheading:15136071-Hyperlipidemias, pubmed-meshheading:15136071-Insulin Resistance, pubmed-meshheading:15136071-Linear Models, pubmed-meshheading:15136071-Lipoprotein Lipase, pubmed-meshheading:15136071-Male, pubmed-meshheading:15136071-Middle Aged, pubmed-meshheading:15136071-Probability, pubmed-meshheading:15136071-Prognosis, pubmed-meshheading:15136071-Reference Values, pubmed-meshheading:15136071-Sensitivity and Specificity, pubmed-meshheading:15136071-Statistics, Nonparametric
pubmed:year
2004
pubmed:articleTitle
Lipoprotein lipase (LPL) mass in preheparin serum reflects insulin sensitivity.
pubmed:affiliation
Department of Homeostatic Regulation and Development, Niigata University Graduate School of Medical and Dental Sciences, Asahimachi 1-757, Niigata 951-8510, Japan.
pubmed:publicationType
Journal Article, Clinical Trial, Comparative Study, Controlled Clinical Trial